

Resource Summary Report

Generated by [dkNET](#) on Aug 19, 2026

UMD p53 Mutation Database

RRID:SCR_006720

Type: Tool

Proper Citation

UMD p53 Mutation Database (RRID:SCR_006720)

Resource Information

URL: <http://p53.fr>

Proper Citation: UMD p53 Mutation Database (RRID:SCR_006720)

Description: The UMD TP53 Mutation Database is a novel web site exclusively dedicated to mutant TP53. The following datasets, analytical tools and software are available. * The TP53 UMD mutation database in human cancer (2012 release). This novel release (35,000 mutations, 3,600 publications) has been highly curated using an original and novel statistical procedure (See Edlung et al. PNAS 2012). * TP53MUTLOAD (MUTant Loss Of Activity Database), a novel database dedicated to detailed analysis of the properties of each TP53 mutant, ranging from transactivation to cell growth properties, change of conformation, localization or various gains of functions. The database contains more than 110,000 different entries. * TP53 Mut assessor, a novel stand-alone software available for both Windows and Mac users. Check your favorite TP53 mutants and get an instant identity card. Very useful to analyze any newly discovered TP53 mutants, as the software checks for every possible TP53 mutation. * MUT-TP53 2.0, an accurate and powerful tool that automatically manages p53 mutations and generate tables ready for publication, decreasing the risk of typing errors. MUT-TP53 2.0 also provides specific information for each TP53 mutation, allowing the user to assess the quality of the data. Up to 500 TP53 mutations can be managed simultaneously.

Abbreviations: p53 Database

Synonyms: UMD TP53 Mutation Database, UMD p53 Database, TP53 UMD mutation database

Resource Type: data or information resource, software application, software resource, database, data processing software

Defining Citation: [PMID:22628563](#)

Keywords: cell, dominant, germline, monoclonal, mutant, mutation, oncogene, p53, phylogenetic, polymorphism, prognosis, somatic, suppression, transform, tumor,

tumorigenesis, umd, cell line

Related Condition: Cancer

Funding: Radiumhemmet Research Funds ;
Cancerföreningen i Stockholm ;
Swedish Cancer Society ;
Swedish Research Council ;
Swedish Cancer Foundation ;
Jeansson Foundation ;
Cancer Society in Stockholm ;
Lions Cancer Research Fund Uppsala

Availability: Limited: The UMD p53 database is protected by the European Union Council Directive N???????????? 96/9/EC, OJ (L77) 20 (1996). Extracting, Copying or reuse of data from databases without permission are covered by this directive.

Resource Name: UMD p53 Mutation Database

Resource ID: SCR_006720

Alternate IDs: nif-0000-21405

Old URLs: http://p53.free.fr/Database/p53_database.html

Record Creation Time: 20220129T080237+0000

Record Last Update: 20260819T044205+0000

Ratings and Alerts

No rating or validation information has been found for UMD p53 Mutation Database.

No alerts have been found for UMD p53 Mutation Database.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 38 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Pavlova S, et al. (2025) Detection of clinically relevant variants in the TP53 gene below 10% allelic frequency: A multicenter study by ERIC, the European Research Initiative on CLL. HemaSphere, 9(1), e70065.

Rida P, et al. (2024) FOXM1 Transcriptionally Co-Upregulates Centrosome Amplification and Clustering Genes and Is a Biomarker for Poor Prognosis in Androgen Receptor-Low Triple-Negative Breast Cancer. *Cancers*, 16(18).

Song R, et al. (2024) Clinical Features of Li-Fraumeni Syndrome in Korea. *Cancer research and treatment*, 56(1), 334.

Malcikova J, et al. (2024) ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-2024 update. *Leukemia*, 38(7), 1455.

Guan L, et al. (2023) Reactivation of mutant p53 in esophageal squamous cell carcinoma by isothiocyanate inhibits tumor growth. *Frontiers in pharmacology*, 14, 1141420.

Delicato A, et al. (2022) In vitro characterization of iridoid and phenylethanoid glycosides from *Cistanche phelypaea* for nutraceutical and pharmacological applications. *Phytotherapy research : PTR*, 36(11), 4155.

Sheng J, et al. (2021) p53-targeted lncRNA ST7-AS1 acts as a tumour suppressor by interacting with PTBP1 to suppress the Wnt/ β -catenin signalling pathway in glioma. *Cancer letters*, 503, 54.

Kiweler N, et al. (2020) Histone deacetylase inhibitors dysregulate DNA repair proteins and antagonize metastasis-associated processes. *Journal of cancer research and clinical oncology*, 146(2), 343.

Palomo L, et al. (2020) Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemia. *British journal of haematology*, 188(5), 605.

Lim J, et al. (2020) Interaction of promyelocytic leukemia/p53 affects signal transducer and activator of transcription-3 activity in response to oncostatin M. *The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology*, 24(3), 203.

Caponio VCA, et al. (2020) Computational analysis of TP53 mutational landscape unveils key prognostic signatures and distinct pathobiological pathways in head and neck squamous cell cancer. *British journal of cancer*, 123(8), 1302.

Schmidt K, et al. (2019) The lncRNA SLNCR Recruits the Androgen Receptor to EGR1-Bound Genes in Melanoma and Inhibits Expression of Tumor Suppressor p21. *Cell reports*, 27(8), 2493.

Kim E, et al. (2019) Mathematical Modeling of p53 Pathways. *International journal of molecular sciences*, 20(20).

Low L, et al. (2019) Targeting mutant p53-expressing tumours with a T cell receptor-like antibody specific for a wild-type antigen. *Nature communications*, 10(1), 5382.

AlHarbi M, et al. (2018) Rare TP53 variant associated with Li-Fraumeni syndrome exhibits variable penetrance in a Saudi family. *NPJ genomic medicine*, 3, 35.

Campo E, et al. (2018) TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics. *Haematologica*, 103(12), 1956.

Malcikova J, et al. (2018) ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation. *Leukemia*, 32(5), 1070.

Ohm AM, et al. (2017) Co-dependency of PKC ϵ and K-Ras: inverse association with cytotoxic drug sensitivity in KRAS mutant lung cancer. *Oncogene*, 36(30), 4370.

Boia-Ferreira M, et al. (2017) TCTP as a therapeutic target in melanoma treatment. *British journal of cancer*, 117(5), 656.

Monti P, et al. (2017) TP63 mutations are frequent in cutaneous melanoma, support UV etiology, but their role in melanomagenesis is unclear. *Oncology reports*, 38(4), 1985.